KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Non-Current Liabilities: 2013-2024

Historic Total Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 12 years, with Dec 2024 value amounting to $1.6 billion.

  • Halozyme Therapeutics' Total Non-Current Liabilities rose 1.27% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1.27%. This contributed to the annual value of $1.6 billion for FY2024, which is 2.06% up from last year.
  • Halozyme Therapeutics' Total Non-Current Liabilities amounted to $1.6 billion in FY2024, which was up 2.06% from $1.6 billion recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Total Non-Current Liabilities ranged from a high of $1.6 billion in FY2024 and a low of $425.4 million during FY2020.
  • Its 3-year average for Total Non-Current Liabilities is $1.6 billion, with a median of $1.6 billion in 2022.
  • Per our database at Business Quant, Halozyme Therapeutics' Total Non-Current Liabilities decreased by 9.47% in 2020 and then spiked by 113.19% in 2021.
  • Halozyme Therapeutics' Total Non-Current Liabilities (Yearly) stood at $425.4 million in 2020, then spiked by 113.19% to $906.9 million in 2021, then surged by 80.72% to $1.6 billion in 2022, then dropped by 1.66% to $1.6 billion in 2023, then grew by 2.06% to $1.6 billion in 2024.